Skip to main content
Top
Published in: Rheumatology International 1/2017

01-01-2017 | Editorial

Cardiovascular risk and inflammation in rheumatic diseases

Author: Armen Yuri Gasparyan

Published in: Rheumatology International | Issue 1/2017

Login to get access

Excerpt

Cardiovascular manifestations of rheumatic diseases have been thoroughly examined over the past decades. It has been established that all structures of the heart can be affected due to the long-term systemic inflammation and specific autoimmune and autoinflammatory factors [1]. Classic clinical models of cardiovascular phenomenon in rheumatic diseases are rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), which are associated with enhanced course of atherosclerosis and various atherothrombotic events. Numerous large cohort studies of RA and SLE have provided evidence of atypical and severe course of myocardial infarction and heart failure in these autoimmune diseases, necessitating specific early diagnostic and preventive approaches. …
Literature
1.
go back to reference Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, Oh JK, Matteson EL, Lerman A (2015) Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12(3):168–176CrossRefPubMed Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, Oh JK, Matteson EL, Lerman A (2015) Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12(3):168–176CrossRefPubMed
2.
go back to reference Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449CrossRefPubMed Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 8(4):437–449CrossRefPubMed
3.
go back to reference Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL (2015) Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem 22(16):1903–1910CrossRefPubMed Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL (2015) Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem 22(16):1903–1910CrossRefPubMed
4.
go back to reference Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL (2015) Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 17:52CrossRefPubMedPubMedCentral Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL (2015) Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 17:52CrossRefPubMedPubMedCentral
5.
go back to reference Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11(11):1781–1794CrossRefPubMed Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11(11):1781–1794CrossRefPubMed
6.
go back to reference Seyahi E, Ugurlu S, Cumali R, Balci H, Ozdemir O, Melikoglu M, Hatemi G, Fresko I, Hamuryudan V, Yurdakul S, Yazici H (2008) Atherosclerosis in Behçet’s syndrome. Semin Arthritis Rheum 38(1):1–12CrossRefPubMed Seyahi E, Ugurlu S, Cumali R, Balci H, Ozdemir O, Melikoglu M, Hatemi G, Fresko I, Hamuryudan V, Yurdakul S, Yazici H (2008) Atherosclerosis in Behçet’s syndrome. Semin Arthritis Rheum 38(1):1–12CrossRefPubMed
7.
go back to reference Gonzalez-Juanatey C, Lopez-Diaz MJ, Martin J, Llorca J, Gonzalez-Gay MA (2007) Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 57(8):1481–1486CrossRefPubMed Gonzalez-Juanatey C, Lopez-Diaz MJ, Martin J, Llorca J, Gonzalez-Gay MA (2007) Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 57(8):1481–1486CrossRefPubMed
8.
9.
go back to reference Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, Uhlig T, Haugeberg G, Kvien TK, Provan SA, Semb AG (2016) Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol 43(9):1622–1630CrossRefPubMed Ikdahl E, Rollefstad S, Wibetoe G, Olsen IC, Berg IJ, Hisdal J, Uhlig T, Haugeberg G, Kvien TK, Provan SA, Semb AG (2016) Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. J Rheumatol 43(9):1622–1630CrossRefPubMed
10.
go back to reference Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ et al (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. doi:10.1136/annrheumdis-2016-209775 (Epub ahead of print) PubMed Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ et al (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2016-209775 (Epub ahead of print) PubMed
Metadata
Title
Cardiovascular risk and inflammation in rheumatic diseases
Author
Armen Yuri Gasparyan
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3619-8

Other articles of this Issue 1/2017

Rheumatology International 1/2017 Go to the issue